TITLE

All-oral hep. C combos threaten interferon

AUTHOR(S)
Iskowitz, Marc
PUB. DATE
June 2012
SOURCE
Medical Marketing & Media;Jun2012, Vol. 47 Issue 6, p16
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the development of an oral drug for treating hepatitis C virus. According to a clinical trial, an all-oral therapy joining daclatasvir from BMS and Gilead Sciences Inc.'s GS-7977 has suppressed the virus in more than 95 percent of patients across a broad spectrum of genotypes. It states that the two drugs has reached a 100 percent sustained virologic response (SVR) in patients not previously treated with interferon.
ACCESSION #
76378534

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics